Therapy of Nonnecrotizing Anterior Scleritis with Subconjunctival Corticosteroid Injection

Elmer Y. Tu, William W. Culbertson, Stephen C. Pflugfelder, Andrew Huang, James C. Chodosh

Research output: Contribution to journalArticlepeer-review

44 Scopus citations


Objective: To determine the safety and efficacy of subconjunctival triamcinolone (Kenalog) in treating nonnecrotizing anterior scleritis. Design: The authors conducted a retrospective review of all patients treated with depot subconjunctival Corticosteroid injection for scleritis from January 1988 to May 1993. Response to therapy was determined by subjective improvement in pain and a decrease in clinical signs of ocular inflammation. All patients received subconjunctival injections of triamcinolone by the same technique, and the minimum observation period for complications was 6 weeks. Results: Eighteen patients (90%) had relief of their symptoms with clinically observable improvement in inflammation, whereas two patients (10%)responded poorly. Nine patients (45%)required no further therapy. Average symptom-free interval was 18 weeks in patients with recurrent scleritis. No complications of scleral thinning, perforation, or glaucoma occurred in any patients. Conclusion: Subconjunctival triamcinolone injection is highly efficacious in treating nonnecrotizing anterior scleritis without unreasonable risk of thinning and jor perforation and should be considered as adjunctive therapy in localized disease.

Original languageEnglish
Pages (from-to)718-724
Number of pages7
Issue number5
StatePublished - 1995


Dive into the research topics of 'Therapy of Nonnecrotizing Anterior Scleritis with Subconjunctival Corticosteroid Injection'. Together they form a unique fingerprint.

Cite this